Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.19.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 108 $ 45
Operating expenses:    
Research and development (related parties of $97 and $259) 977 1,124
General and administrative (related parties of $321 and $238) 2,986 2,871
Total operating expenses 3,963 3,995
Operating loss (3,855) (3,950)
Other income (expense):    
Interest expense -related party (620) (476)
Interest income 4 21
Royalty income 7 6
Total other income (expense) (609) (449)
Consolidated net loss (4,464) (4,399)
Net loss attributable to noncontrolling interest 1 1
Net loss attributable to iBio, Inc. (4,463) (4,398)
Preferred stock dividends (66) (66)
Net loss available to iBio, Inc. (4,529) (4,464)
Comprehensive loss:    
Consolidated net loss (4,464) (4,399)
Other comprehensive loss - foreign currency translation adjustments (1) (1)
Comprehensive loss $ (4,465) $ (4,400)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.21) $ (0.25)
Weighted-average common shares outstanding - basic and diluted 21,923 17,894